Skip to content

Author

Kamal A. Hamed

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Oct 2026

No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies

Abstract Objective Ceftibuten and ledaborbactam etzadroxil are being developed as an oral fixed-dose combination for the treatment of complicated urinary tract infections caused by multidrug-resistant Enterobacterales. This study evaluated their effects on cardiac repolarization using concentration-QTc analyses. Method...

B. Darpo, Hong-Qi Xue, Kamal A. Hamed et al. · 0 citations
Open access Sep 2026

Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment

Dose adjustment of ceftibuten-ledaborbactam etzadroxil will be required for patients with reduced renal function, as decreasing renal function was associated with increased plasma exposure and reduced renal clearance.

C. F. de Oliveira, K. Lowe, Penny Fatato et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.